Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

83.59 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,692
Open 83.59
Bid (Size) 87.93 (8)
Ask (Size) 88.00 (30)
Prev. Close 83.59
Today's Range 83.59 - 83.59
52wk Range 74.09 - 94.26
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
New research project aims to set standardized approach to lipoprotein(a) management
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
How Is The Market Feeling About Novartis?
 
Via Benzinga

Performance

YTD
-9.35%
-9.35%
1 Month
-2.37%
-2.37%
3 Month
-8.27%
-8.27%
6 Month
+12.04%
+12.04%
1 Year
-3.91%
-3.91%

More News

Read More
2 Biotech Stocks That Could Make You Richer
Via The Motley Fool
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo
Via Benzinga
Novartis Reveals Long-Term Data Of Atrophy Gene Therapy Exhibiting Sustained Durability Of Up To 7.5 Years
Via Benzinga
FDA Approves Novartis' Tafinlar + Mekinist For Pediatric Brain Cancer With Certain Mutations
Via Benzinga
This High-Yielding Blue Chip Stock Is a Strong Buy
Via The Motley Fool
Elon Musk Frets As Microsoft Axes AI Ethics Team, Richard Branson's Virgin Orbit Stops Ops, Credit Suisse To Borrow Up To $54B: Today's Top Stories
Via Benzinga
Novartis' Prostate Cancer Therapy Hit By Supply Crunch, Seeks To Ramp Up Production To Ease Supply Issues
Via Benzinga
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
Via FinancialNewsMedia
Exposures Product Safety
3 High Dividend Stocks With Attractive Total Return Potential
Via InvestorPlace
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via News Direct
Topics Economy
Exposures Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via TheNewswire.com
Topics Economy
Exposures Supply Chain
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Via Benzinga
4 AI Stocks That Are Revolutionizing Healthcare
Via InvestorPlace
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier?
Via Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Via Talk Markets
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
Via Benzinga
Better Buy: Beam Therapeutics or Intellia Therapeutics?
Via The Motley Fool
Lupus Therapeutics Market Is on the Verge of Crossing at High CAGR of 9% in 2022-2029
Via SBWire
Bladder Prolapse (Cystocele) Market to Touch at High CAGR of 8.3% by 2022-2029
Via SBWire
Choroidal Neovascularization Market Share Size Trends Overview Analysis 2022-2029
Via SBWire
Occupational Medicines Market Is Expected to Reach at High CAGR of 5.4% by 2022-2029
Via SBWire
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
Via Benzinga
Water for Injection Market Trends Outlook Demand 2023 -2030
Via SBWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.